Journal: Scientific reports
This study assessed the safety and feasibility of two neoadjuvant chemotherapy regimens—gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS)—in elderly patients (≥75 years) with resectable and borderline resectable pancreatic ductal adenocarcinoma.
A post hoc analysis of a randomized controlled trial compared outcomes between elderly and younger patients, focusing on:
- Resection rates
- Adverse events
- Postoperative complications
- Adjuvant chemotherapy administration
While adverse events were more frequent in the elderly, the differences were not statistically significant. Importantly, resection rates, postoperative complications, and adjuvant therapy use were similar regardless of age.
Both regimens demonstrated comparable safety profiles across age groups, supporting their use as feasible neoadjuvant options for elderly patients with this cancer type.
Further trials are encouraged to confirm these findings in the elderly population.